The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | DR-01, an anti-CD94 monoclonal antibody, in the treatment of ultra-rare cytotoxic T-cell lymphomas
Swaminathan Iyer, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the potential of DR-01, a non-fucosylated anti-CD94 monoclonal antibody, in treating ultra-rare cytotoxic T-cell lymphomas. Prof. Iyer notes that DR-01 has shown promising results in a Phase I/II clinical study (NCT05475925), with some patients achieving complete and partial responses. This trial is now being considered as a registration study looking at an expansion with one of the doses. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Cytotoxic T-cell lymphomas are ultra-rare T-cell lymphomas that span from NK T-cell extranodal to the rare varieties like the gamma, delta T-cell lymphomas, hepatosplenic to cutaneous to the cytotoxic nodal T-cell lymphomas, EBV or otherwise. And so it’s an ultra-rare disease and the outcomes are very poor for this group of patients. But the cell of origin unites them all because they’re all cytotoxic...
Cytotoxic T-cell lymphomas are ultra-rare T-cell lymphomas that span from NK T-cell extranodal to the rare varieties like the gamma, delta T-cell lymphomas, hepatosplenic to cutaneous to the cytotoxic nodal T-cell lymphomas, EBV or otherwise. And so it’s an ultra-rare disease and the outcomes are very poor for this group of patients. But the cell of origin unites them all because they’re all cytotoxic. They are either NK or cytotoxic CD8 positive. So there’s also another common marker which is CD94. So DR-01 is an anti-CD94 monoclonal antibody that again started as a first in human and now expanded to a Phase II study. And we have an oral presentation today that my colleague Dr Jasmine Zain is doing. But we enrolled the most number of patients and we looked at the dose escalation of the Phase I portion and several of these ultra T-cell lymphomas who actually achieved a CR and partial responses at various dose levels. Currently, the Phase II is looking at one milligram and six milligram per kilogram dose levels and most of the responses are seen in the one milligram per kilogram dose levels and that’s the data that she will present and it’s now considered as a registration study looking at an expansion with one of the doses that we will pick. And we’ll have several of these patients who otherwise don’t have a standard of care. The outcomes are really poor. So I think it’s a major advance for this ultra-rare T-cell lymphoma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Acrotech: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Ono: Research Funding; Merck: Research Funding; Yingli: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Astra Zeneca: Research Funding; IMPaRT.AI: Other: Stock, Founder; Salarius: Consultancy; Innate: Research Funding; Secura Bio: Membership on an entity’s Board of Directors or advisory committees; Legend: Research Funding; Trillium: Research Funding; Crispr: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Seagen/Pfizer: Membership on an entity’s Board of Directors or advisory committees, Research Funding; JCO-CCI: Other: Editor.
